Acute Tubular Injury in a Patient on a Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor

June K. Pickett, MD; Maulin Shah, MD; Michael Gillette, PharmD; Peter Jones, MD; Salim Virani, MD, PhD; Christie Ballantyne, MD; Vijay Nambi, MD, PhD

JACC: Case Reports (Jun 2020)

Acute Tubular Injury in a Patient on a Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor

June K. Pickett, MD,
Maulin Shah, MD,
Michael Gillette, PharmD,
Peter Jones, MD,
Salim Virani, MD, PhD,
Christie Ballantyne, MD,
Vijay Nambi, MD, PhD

Affiliations

June K. Pickett, MD: Department of Medicine, Baylor College of Medicine, Houston, Texas
Maulin Shah, MD: Department of Medicine, Baylor College of Medicine, Houston, Texas; Michael E DeBakey Veterans Affairs Hospital, Houston, Texas; Section of Nephrology, Baylor College of Medicine, Houston, Texas
Michael Gillette, PharmD: Michael E DeBakey Veterans Affairs Hospital, Houston, Texas
Peter Jones, MD: Department of Medicine, Baylor College of Medicine, Houston, Texas
Salim Virani, MD, PhD: Department of Medicine, Baylor College of Medicine, Houston, Texas; Michael E DeBakey Veterans Affairs Hospital, Houston, Texas
Christie Ballantyne, MD: Department of Medicine, Baylor College of Medicine, Houston, Texas
Vijay Nambi, MD, PhD: Department of Medicine, Baylor College of Medicine, Houston, Texas; Michael E DeBakey Veterans Affairs Hospital, Houston, Texas; Division of Atherosclerosis and Vascular Medicine, Methodist DeBakey Heart and Vascular Center, Methodist Hospital, Houston, Texas; Address for correspondence: Dr. Vijay Nambi, Baylor College of Medicine, 6565 Fannin Street, MS A601/STE B160, Houston, Texas 77030.

Journal volume & issue: Vol. 2, no. 7
pp. 1042 – 1045

Abstract

Read online

A 72-year-old man with coronary artery disease, statin intolerance, and chronic kidney disease stage IIIa was initiated on alirocumab, a proprotein convertase subtilisin/kexin type 9 inhibitor, and developed acute kidney injury. A kidney biopsy was performed and suggested acute tubular injury. The serum creatinine returned to baseline after discontinuation of alirocumab. (Level of Difficulty: Intermediate.)

Published in JACC: Case Reports

ISSN: 2666-0849 (Online)
Publisher: Elsevier
Country of publisher: United States
LCC subjects: Medicine: Internal medicine: Specialties of internal medicine: Diseases of the circulatory (Cardiovascular) system
Website: https://www.journals.elsevier.com/jacc-case-reports

About the journal

Abstract

Keywords